Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

54 results about "Protein-Tyrosine Kinases" patented technology

Application of sequential combination CAR T in preparation of antitumor drugs based on improvement of tumor microenvironment

The invention discloses a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T and application of the sequential anti-tumor strategy, belongs to the technical field of biological medicine, and particularly relates to a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T. According to the strategy, tumor fibrosis and an acidic microenvironment are improved at the same time by applying a tumor-associated fibroblast (CAF) targeted drug and a proton pump inhibitor, and then sequential injection of CAR T is performed for combined treatment of solid tumors. Wherein the CAF targeting drug is selected from all-trans retinoic acid, calcipotriol, losartan and minetil, the proton pump inhibitor is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy firstly destroys a compact physical barrier of a tumor microenvironment, improves acidity of a tumor site, ensures infiltration, survival and proliferation of CAR T at the tumor site, and then utilizes specificity of CAR T to inhibit growth of solid tumors in a targeted manner, especially triple negative breast cancer with a high malignancy degree.
Owner:CHINA PHARM UNIV

Protein tyrosine kinase inhibitor and medical use thereof

PendingUS20260049071A1Organic active ingredientsSenses disorderDiabetic retinopathyOcular bioavailability
The present invention relates to a protein tyrosine kinase inhibitor for the treatment of protein tyrosine kinase-mediated proliferative diseases or symptoms, for example ocular diseases including pathological neovascularization, retinal ischemia, retinal edema, and diabetic retinopathy, as well as malignant tumors. More particularly, the present invention relates to a compound with protein tyrosine kinase inhibitory activity and / or improved solubility and ocular bioavailability, and its uses in the treatment of ocular diseases and malignant tumors.
Owner:BEYOND THERAPEUTICS CO LTD

Norsesquiterpenoids as well as preparation method and application thereof

The invention belongs to the field of natural medicines, and relates to a norsesquiterpenoids compound mycehainanic acid which is derived from branches and leaves of Adenocalyx hainanensis of a rubiaceae Adenocalyx plant and has a novel chemical structure, a preparation method of the norsesquiterpenoids compound, and application of the norsesquiterpenoids compound mycehainanic acid in antitumor medicines. Various in-vitro activity evaluation results of the compound mycehainanic acid show that the compound has remarkable anti-tumor activity and protein tyrosine kinase inhibition activity equivalent to that of a positive control drug, and can be further developed into an anti-tumor drug taking protein tyrosine kinase as a target, so that the medicinal value and the economic value of the compound are fully exerted; and the separation and purification process is simple and has practical significance.
Owner:HAINAN NORMAL UNIV

Novel inhibitors of phosphatidylinositol 3-kinase

This invention relates to the prevention and / or treatment of protein tyrosine kinase-mediated diseases, particularly phosphatidylinositol 3-kinase (PI3Ks)-mediated diseases. PI3Ks are well known as oncological targets, and several PI3K inhibitors have been developed that inhibit numerous class 1A PI3K isoforms. The development of selective inhibitors of PI3K-α may enable sufficient targeted inhibition while avoiding some of the known toxic drawbacks of pan-PI3K inhibitors. The inventors have discovered that a novel carbamoti-oil-pyrrolidine-carboxamide compound of formula (I) exhibits advantageous PI3K inhibitory activity, particularly with high selectivity for the isoform PI3K-α. In particular, this invention relates to the compound of formula (I), or deuterated or tritiated forms of the compound of formula (I), and pharmaceutically acceptable salts thereof. [Formula 1] The present invention also relates to pharmaceutical compositions containing a compound of formula (I) for use in the treatment and / or prevention of protein tyrosine kinase-mediated diseases, and to a compound of formula (I).
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Xanthone compound as well as preparation method and application thereof

The invention relates to the field of natural medicines, and discloses a xanthone compound which is derived from leaves and branches of cratoxylum cochinchinensis and has a novel chemical structure, a preparation method of the xanthone compound and application of the xanthone compound in antitumor medicines, and various in-vitro antitumor activity evaluation results of the compound cratocochinone show that the compound has remarkable antitumor activity and can be used for preparing antitumor drugs. The compound has the protein tyrosine kinase inhibition activity equivalent to that of a positive control drug, can be further developed into an anti-tumor drug taking protein tyrosine kinase as a target, has a wide application prospect, is simple in separation and purification process, and has practical significance.
Owner:HAINAN NORMAL UNIV

Antibodies and methods for ptk7 detection

The present disclosure provides antibodies that specifically bind to protein tyrosine kinase 7 (PTK7), and methods of using such antibodies. In some cases, the PTK7 antibodies are used in an immunohistochemistry (IHC) assay, which can detect the presence of cells expressing PTK7 in a tissue from a patient.
Owner:GENMAB AS

Antibodies and methods for PTK7 detection

The present disclosure provides antibodies that specifically binds to protein tyrosine kinase 7 (PTK7), as well as methods that employ such antibodies. In some cases, the PTK7 antibodies are used in immunohistochemistry (IHC) assays that can detect the presence of PTK7 expressing cells in tissues from patients.
Owner:GENMAB AS

Application of sequential combination of CAR T based on improvement of tumor microenvironment in preparation of anti-tumor drugs

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.
Owner:CHINA PHARM UNIV

A norosequiterpenoid compound and its preparation method and application

The present invention belongs to the field of natural medicines and relates to a norosequiterpenoid compound, mycehainanic acid, with a novel chemical structure and derived from the branches and leaves of a plant of the genus Adenocalyx in the Rubiaceae family, as well as a preparation method thereof and an application thereof in anti-tumor drugs. The results of multiple in vitro activity evaluations of the compound mycehainanic acid show that the compound has significant anti-tumor activity and protein tyrosine kinase inhibitory activity comparable to that of a positive control drug. The compound can be further developed into an anti-tumor drug targeting protein tyrosine kinase, thereby fully realizing its medicinal and economic value. The separation and purification process is simple, and the compound has practical significance.
Owner:HAINAN NORMAL UNIV

A xanthone compound and its preparation method and application

The present invention relates to the field of natural medicines, and discloses a xanthone compound with a novel chemical structure derived from the branches and leaves of the yellow cattle wood, a preparation method thereof, and an application of the compound in anti-tumor drugs. The compound, cratocochinone, has been evaluated by multiple in vitro anti-tumor activities and has significant anti-tumor activity and an activity of inhibiting protein tyrosine kinase equivalent to that of a positive control drug. The compound can be further developed into an anti-tumor drug targeting protein tyrosine kinase, has broad application prospects, and has a simple separation and purification process, thus having practical significance.
Owner:HAINAN NORMAL UNIV

Protein tyrosine kinase 7 antibodies and antibody-drug conjugates

The present disclosure provides PTK-7 antibody drug conjugates and pharmaceutical compositions thereof, and methods of using for the treatment of cancer.
Owner:ELI LILLY & CO

Engineered immune cells

To provide an immune cell expressing a chimeric antigen receptor, wherein the immune cell is modified such that the expression and / or function of lymphocyte-specific protein tyrosine kinase is reduced or eliminated.SOLUTION: An immune cell expressing a chimeric antigen receptor is provided, wherein the chimeric antigen receptor comprises an intracellular signaling domain or a fragment thereof that functions in the absence of lymphocyte-specific protein tyrosine kinase, and the immune cell is modified such that the expression and / or function of lymphocyte-specific protein tyrosine kinase is reduced or eliminated.SELECTED DRAWING: None
Owner:NATIONAL UNIVERSITY OF SINGAPORE

Novel inhibitors of phosphatidylinositol 3-kinase

The invention relates to prevention and / or treatment of diseases mediated by protein tyrosine kinase, in particular to diseases mediated by phosphatidylinositol 3-kinase (PI3K). PI3K is known as an oncology target, and a variety of PI3K inhibitors have been developed, which inhibit a variety of 1A class PI3K subtypes. Development of PI3K-alpha selective inhibitors may enable sufficient target inhibition while avoiding some known toxic defects of pan-PI3K inhibitors. The inventor finds that a novel thiocarbamoyl-pyrrolidine-carboxamide compound of a specific formula (I) shows excellent PI3K inhibitory activity, and especially has high selectivity for subtype PI3K alpha. In particular, the present invention relates to a compound of formula (I), or a deuterated or tritiated form of a compound of formula (I), and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I), and to the use of the compound of formula (I) for the treatment and / or prevention of protein tyrosine kinase mediated diseases. # imgabs0 #
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Compound having protein tyrosine kinase BTK-degrading activity, and preparation method therefor and use thereof

PCT designated stageWO2025162210A1Organic active ingredientsOrganic chemistryDiseaseTyrosine Protein Kinases
The present application relates to the field of pharmaceutical chemistry, and specifically to a Bruton's tyrosine kinase (BTK) as shown in formula (I) and a mutant degrader thereof, a pharmaceutically acceptable salt thereof, a deuterated compound thereof, a stereoisomer thereof, a tautomer thereof, or a mixture thereof, and a use thereof in the preparation of a drug for treating diseases or disorders mediated by degradation of BTK.
Owner:SHANGHAI HELIOSON PHARM CO LTD

Small-molecule modulators of lymphocyte-specific protein tyrosine kinase and casein kinase 1a

The present disclosure, in one aspect, relates to small molecules useful as modulators of cereblon protein. In another aspect, the present disclosure relates to small molecules useful as modulators of lymphocyte-specific protein tyrosine kinase (LCK) and / or casein kinase 1a (CK1a), methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with a LCK and / or CK1a protein dysfunction.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC

Protein tyrosine kinase inhibitor and medical application thereof

The present invention relates to a protein tyrosine kinase inhibitor and its use in the prevention and / or treatment of protein tyrosine kinase mediated hyperproliferative diseases, such as ocular diseases and malignant tumors associated with pathological neovascularization. The protein tyrosine kinase inhibitor not only can effectively antagonize the activity of VEGFR receptor tyrosine kinase, but also improves the pharmacokinetic property of the VEGFR receptor tyrosine kinase, and has high selectivity for inhibiting the activity of off-target EGFR tyrosine kinase so as to reduce or avoid adverse effects, especially side effects on eyes.
Owner:BEYOND THERAPEUTICS CO LTD

Cyclic molecules as Bruton's tyrosine kinase inhibitor

The present invention relates to a novel molecule with protein tyrosine kinase inhibitory activity, and the synthesis and usage thereof. Specifically, the present invention relates to compound by formula A, pharmaceutically acceptable salts, hydrates or solvates thereof, and the synthesis and usage thereof.
Owner:MINGHUI PHARMA (SHANGHAI) LTD +1

Antibodies and uses thereof

PendingUS20260250421A1AntigenProtein-Tyrosine Kinases
The anti-PTK7 (protein tyrosine kinase 7) antibodies, antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom; anti-TROP2 (trophoblast cell surface antigen 2) antibodies, antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom; and anti-PTK7 / TROP2 (e. g., multispecific or bispecific) antibodies or antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom and uses thereof are disclosed.
Owner:BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD

New inhibitors of phosphatidylinositol 3-kinase

PendingUS20260248775A1DiseaseProtein-Tyrosine Kinases
The prevention and / or treatment of protein tyrosine kinase mediated diseases, in particular phosphatidylinositol 3-kinases (PI3Ks) mediated diseases. PI3Ks are well-known as oncology targets and several inhibitors of PI3Ks have been developed that inhibit multiple class 1A PI3K isoforms. The development of selective inhibitors of PI3K-α may enable sufficient target inhibition while avoiding some toxicity drawbacks known for pan PI3K inhibitors. New specific carbamothioyl-pyrrolidine-carboxamide compounds of formula (I) exhibit an advantageous PI3K inhibitory activity, especially with a high selectivity for the isoform PI3K alpha. In particular, compounds of formula (I), or a deuterated or tritiated form of the compound of formula (I), and pharmaceutically acceptable salts thereof:Also, a pharmaceutical composition containing the compound of formula (I) and the compounds of formula (I) for use in the treatment and / or prevention of Protein tyrosine kinase mediated diseases.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Immunohistochemical (IHC) PTK7 scoring regimens and methods for adjunctive cancer therapy

In alternative embodiments, provided are immunohistochemical (IHC) methods and kits for reproducibly determining and scoring the degree of expression of protein tyrosine protein kinase-like 7 (PTK7), also known as colon cancer kinase 4 (CCK4), in a tissue sample; hER2 or a receptor tyrosine protein kinase erbB-2, or a cluster of differentiation 340 (CD340); a programmed death ligand 1 (PD-L1) or a differentiation cluster 274 (CD274); a B7 homolog 1 (B7-H1); and Ki-67 or MKI67 (a proliferation marker Ki-67), as well as a use thereof. In alternative embodiments, methods and kits are provided for diagnosing or selecting an individual eligible for treatment with a cancer or tumor therapeutic agent, or assessing the risk of cancer or tumor recurrence using an IHC method as provided herein. In alternative embodiments, kits comprising components and instructions for performing the methods as provided herein are provided. Described herein are methods for scoring PTK7 expression and utilizing the score as a companion or supplemental diagnosis to help treat or ameliorate cancer or tumor.
Owner:AGILENT TECHNOLOGIES INC

Protein tyrosine kinase inhibitors and their medical uses

The present invention relates to protein tyrosine kinase inhibitors and their use in the prevention and / or treatment of hyperproliferative diseases mediated by protein tyrosine kinases, such as ocular diseases and malignant tumors associated with pathological neovascularization. In addition to effectively antagonizing VEGFR receptor tyrosine kinase activity, the protein tyrosine kinase inhibitors have improved pharmacokinetic properties and can highly selectively inhibit "off-target" EGFR tyrosine kinase activity, thereby reducing or avoiding adverse effects, particularly ocular side effects.
Owner:BEYOND THERAPEUTICS CO LTD

Antibodies and methods for PTK7 detection

The present disclosure provides antibodies that specifically binds to protein tyrosine kinase 7 (PTK7), as well as methods that employ such antibodies. In some cases, the PTK7 antibodies are used in immunohistochemistry (IHC) assays that can detect the presence of PTK7 expressing cells in tissues from patients.
Owner:GENMAB AS

Methods for treating traumatic brain injury

The disclosure provides compositions and methods for treating traumatic brain injury (TBI). The compositions comprise inhibitors of multiple protein tyrosine kinase families, including Src, Abl, and / or c-Kit protein tyrosine kinase families. The methods comprise administering a therapeutically effective amount of a composition comprising an inhibitor of multiple protein tyrosine kinase families to a subject, wherein the inhibitor is administered at a dose of less than about 20 mg / day to an adult human.
Owner:RGT UNIV OF CALIFORNIA